Abstract: The present invention provides a trialkoxysilane having structure I wherein R1 is independently at each occurrence a C1-C3 alkyl group; R3 is independently at each occurrence a hydrogen or a C1-C3 alkyl group; R4 is a C1-C5 aliphatic radical, a C7-C12 aromatic radical, or a C5-C10 cycloaliphatic group; n is 0, 1, 2 or 3; q is 1, 2 or 3; t is 0, 1 or 2; and X? represents a charge balancing counterion. The trialkoxysilanes are useful for the preparation of nanoparticulate diagnostic imaging agent compositions.

Abstract: To provide novel carboxamides which exhibit an excellent pesticidal activity as pesticides. Carboxamides represented by the following Formula (I) and use thereof as pesticides and an animal parasite control agent: wherein each substituent is as defined in the specification.

Abstract: The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I): RxSi(OH)4-x, (I) wherein: R is a (C1-C4)alkyl, and x=1 or 2. The invention also concerns the use of such a complex in the prevention or the repair of cutaneous damages.

Abstract: Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

Abstract: The present invention relates to compounds of Formula (I), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iGluR receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iGluR receptors.

Abstract: To provide An external skin agent that prevents onset of atopic skin inflammations and is low irritant to skin, which is characterized by including: 1) clay modified by a compound having a quaternary amino group; and 2) a polymer or copolymer that has a side chain including a structure similar to a biological component.

Abstract: Metallocene compounds and pharmaceutical compositions containing these metallocene compounds are disclosed and described. Methods of treating cancer employing such metallocene compounds and pharmaceutical compositions also are provided.

Abstract: The present invention provides compounds of Formula (I): (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):

Abstract: Silicon precursors for forming silicon-containing films in the manufacture of semiconductor devices, such as films including silicon carbonitride, silicon oxycarbonitride, and silicon nitride (Si3N4), and a method of depositing the silicon precursors on substrates using low temperature (e.g., <550° C.) chemical vapor deposition processes, for fabrication of ULSI devices and device structures.

Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I).

Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein Z is O or S; and R1, R2, R3, Q and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling a parasitic nematode comprising contacting the parasitic nematode or its environment with a biologically effective amount of a compound or a composition of the invention.

Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

Abstract: The invention provides silicate prodrugs comprising a therapeutic agent linked to one or more groups of formula (I): —Si(OR)3 (I); wherein each R independently has any of the values defined herein, as well as nanoparticles comprising such compounds.

Abstract: Disclosed herein are novel compounds of formula (I), and uses thereof. The compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds of Formula (I) for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g.

Abstract: Heteroarylpiperidine and -piperazine derivatives of the formula (I) in which the symbols A, X, Y, L1, L2, G, Q, p, R1, R2 and R10 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi and processes for preparing compounds of the formula (I).

Abstract: The invention relates to a composition, especially a cosmetic composition, comprising: (i) one or more alkoxysilanes, (ii) one or more fatty esters; and (iii) one or more silicones. The invention also relates to a cosmetic process for treating keratin materials with this composition, and also to the use of this composition for caring for and/or shaping keratin materials.

Abstract: The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Abstract: The present invention relates to pesticidal mixtures comprising as active compounds 1) at least one pesticidal active 3-arylquinazolin-4-one compound I of formula (I): wherein R1, R2, R3, R4, k and n are defined in the description; and 2) at least one fungicidal compounds II selected from azoles, strobilurins, carboxamides, carbamates, heterocyclic and various other compounds as defined in the description, in synergistically effective amounts. The invention relates further to methods and use of these mixtures for combating insects, arachnids or nematodes and harmful fungis in and on plants, and for protecting such plants being infested with pests, especially also for protecting seeds.

Abstract: The invention relates to concentrated liquid cleansing compositions in lamellar phase which possess a lotion-like appearance conveying signals of enhanced moisturization. The use of a specific ratio of synthetic anionic surfactant(s) and co-surfactant(s) to fatty acid(s) in a structured liquid product was found to improve lather production by moderating or eliminating the increase in viscosity upon dilution. In a further embodiment, specific small hydrophobic molecules were found to improve freeze/thaw stability and thereby cause the inventive composition to maintain noticeable moisturization signals.

Abstract: The present invention relates to pyrazole carboxamides derivatives of formula (1) wherein Y represents CR5 or N, T represents S or O, X1 and X2 represent a chlorine or a fluorine atom, and Z1 represents a substituted or non-substituted cyclopropyl; Their process of preparation, their use as fungicide, and/or anti-mycotoxin active agents, and/or insecticide, and/or nematicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.

Abstract: Nanoparticles, which are luminescent and/or electroactive and/or suitable for MRI (magnetic resonance imaging and/or PET (positron emission tomography) applications, comprise a micelle, which has a hydrophilic shell and an hydrophobic central portion, and a polysilicate core; the micelle comprises a plurality of molecules of a functionalized surfactant having the following structure: M1-Hydro1-Lipo-Hydro2-M2 wherein Lipo indicates a hydrophobic chain; Hydro1 ed Hydro2 indicate, each, a respective hydrophilic chain; M1 ed M2 represent respective recognition functionalities.

Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.

Abstract: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

Abstract: The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: The present invention discloses a cosmetic preparation which comprises 20 mass % or more of an oil ingredient comprising the following components (A) and (B), and said oil ingredient comprising 50 mass % or more of the component (B): (A): one or more members selected from the group consisting of an ester compound(s) represented by the following formula (I) and/or formula (II) of erythritol and/or erythritol condensate with a fatty acid(s); polycondensates of erythritol and/or erythritol condensate, the above-mentioned ester compound(s) and a polycarboxylic acid(s); polycondensates of a fatty acid(s) with a polycondensate(s) of erythritol and/or erythritol condensate with a polycarboxylic acid(s); and polycondensates of erythritol and/or erythritol condensate, a fatty acid(s) and a polycarboxylic acid(s); and (B): silicone. This cosmetic preparation is excellent in compatibility with an oil agent and affinity for a water-base component.

Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.

Abstract: The present application relates to active compound combinations of pyrazin-2-ylpyrazoles (component A) with at least one further ectoparasiticide or synergists (component B), and to products comprising such active compound combinations. These active compound combinations are suitable for controlling animal pests in the field of veterinary medicine.

Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

Abstract: Provided is a novel protein phosphatase inhibitor. The protein phosphatase inhibitor contains, as an active ingredient, a silicon compound represented by the following general formula (1) or a salt thereof, wherein R1, R2 and R3 are the same or different and represent a hydrocarbon group having 1 to 12 carbon atoms; X represents an optionally substituted hydrocarbon group having 3 to 36 carbon atoms or an optionally substituted heterocyclic group; and n represents an integer of 0 or 1.

Abstract: The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage.

Abstract: A method of treating a grass-carrying surface, the method comprising applying to the g carrying surface: (a) a compound of formula (I): or a derivative salt thereof wherein L is a linking group; each of R1, R2 and R3 is independently selected from an optionally substituted alkyl, alkenyl, aryl or alkoxy group; R4 is oxygen or an optionally substituted alkyl, alkenyl or aryl group; each of R5 and R6 is an optionally substituted alkyl, alkenyl or aryl group; and n is 0 or 1; (b) at least one cationic biocide; (c) a hydrocarbyl saccharide compound; and (d) a nonionic surfactant.

Abstract: Antimicrobial granules comprise carrier particles agglomerated by a binding agent containing a quaternary ammonium organosilane.

Abstract: Methods and compositions using an orthosilicate for tissue regeneration, such as to treat a disease or condition, are described, including on the skin. Also described are methods for making such compositions.

Abstract: The present invention provides compounds of formula (I) wherein G1, G2, G3, G4, G5, G6, Y1, Y2, Y3, Y4, Y5 and Y6 and p and q are as defined in the claims. The invention further relates to compositions which comprise these compounds and to their use in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

Abstract: The present application relates to novel substituted aryloxazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

Abstract: The invention relates to concentrated liquid cleansing compositions in lamellar phase which possess a lotion-like appearance conveying signals of enhanced moisturization. The use of a specific ratio of synthetic anionic surfactant(s) and co-surfactant(s) to fatty acid(s) in a structured liquid product was found to improve lather production by moderating or eliminating the increase in viscosity upon dilution. In a further embodiment, specific small hydrophobic molecules were found to improve freeze/thaw stability and thereby cause the inventive composition to maintain noticeable moisturization signals.

Abstract: The present invention relates to the use of topical compositions containing bromociclen for the prevention and/or treatment of various types of dermatitis, in particular eczema and psoriasis.

Abstract: This invention relates to a solid pharmaceutical composition that include a regulating agent of digestive and/or intestinal motility which has an agonist effect on peripheral ?, ? and ? opiate receptors; and an antiflatulent for the treatment and regulation of intestinal motility and flatulence in mammals. More in particularly, the pharmaceutical composition includes: (a) at least a regulating agent of intestinal motility such as trimebutine; (b) at least an antiflatulent such as simethicone; (c) at least a flowability promoter; (d) one or more lubricant; (e) at least an extender/diluent; (f) at least a disintegrant; and, (g) at least a binder.

Abstract: A kind of new compounds, and their pharmaceutically acceptable salts, and hydrates are disclosed. The pharmaceutical composition thereof is also provided. And also are the medical uses of the compounds, pharmaceutically acceptable salts, hydrates and the pharmaceutical composition for treating the TRPV1-mediate diseases.

Abstract: Provided is a cosmetic composition which has a structure-recovering property, is transparent, is satisfactory in smoothness when applied to the skin or hair, and has a good feeling in use, which comprises components (A) to (D) as described.

Abstract: Disclosed herein are a process or method for the preparation of prasugrel and several novel crystalline forms of prasugrel hydrochloride. The process comprises preparation of prasugrel by acetylation in solvents which have low boiling point and/or low toxicity, and the process not only avoids using solvents which have high boiling point and/or high toxicity such as toluene, acetonitrile and so on, but also resolves the problem about thermal instability of prasugrel, and the loss of prasugrel is reduced, as well as the yield is raised. The yield of prasugrel is higher than 85% and the purity is higher than 99.5%. The process can prepare prasugrel and its pharmaceutically acceptable salts. The novel crystalline forms of prasugrel hydrochloride are crystalline form H1, H2 and H3, and their performance in oral absorbability, activating metabolism and inhibiting platelet aggregation is excellent.

Abstract: The present invention relates to a cosmetic process for treating keratin materials, which can give them, especially in a long-lasting and reversible manner, interesting cosmetic properties; this process comprising the application to said materials: in a first stage, of a cosmetic composition comprising at least one graftable species, comprising at least one unit of formula (Ia): and in a second stage, of a cosmetic composition comprising at least one cosmetic active agent bearing at least one unit of formula (Ia): The invention also relates to a kit comprising said compositions.

Abstract: A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide, a carbonyl ethoxy tripeptide; a primary alcohol modified to form an esterified single amino acid, dipeptide or tripeptide of zanavimir of the unaltered therapeutic agent. Exemplary therapeutic agents so modified to form prodrugs include zanavimir, oseltamivir and peramivir. The prodrug has increased oral bioavailability relative to the unaltered neuraminidase inhibitor and is effective in the inhibition of viral infections involving neuraminidase in the viral reproductive cycle.

Abstract: Fungicidal mixtures comprising, as active components, 1) azolopyrimidinylamines of the formula I, in which the substituents are as defined in the description and 2) at least one active compound II selected from the following groups: azoles, strobilurins, carboxamides, heterocylic compounds, carbamates and other active compounds selected from the group consisting of guanidines, antibiotics, sulfur-containing heterocyclyl compounds, organophosphorus compounds, organochlorine compounds, inorganic active compounds, growth retardants and cyflufenamid, cymoxanil, dimethirimol, ethirimol, furalaxyl, metrafenone and spiroxamine; in a synergistically effective amount. Methods for controlling harmful fungi using mixtures of the compound I with active compounds II and the use of the compound I with active compounds II for preparing such mixtures, and also compositions comprising these mixtures.

Abstract: The present invention relates to pyrazole carboxamides derivatives of formula (1) wherein Y represents CR5 or N, T represents S or O, X1 and X2 represent a chlorine or a fluorine atom, and Z1 represents a substituted or non-substituted cyclopropyl; Their process of preparation, their use as fungicide, and/or anti-mycotoxin active agents, and/or insecticide, and/or nematicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.

Abstract: The invention is directed to novel 17?-heteroaryl substituted steroids of Formula I, pharmaceutical compositions thereof, and their use as modulators of GABAA receptors.

Abstract: The present invention is directed to an insect repelling device that may serve as an effective barrier against ticks. The insect repelling device may include a band of technical fabric, with the fabric being very stretchable. The insect repelling device may be worn around the ankles, wrist or head. The insect repelling device may be worn in pairs on each ankle and/or wrist. The insect repelling device may have an open, tubular design and be made of a high performance, nylon/ polyester fabric, allowing a user to easily insert the foot or hand and fit the device around the ankle or wrist area. Each insect repelling device may be pre-treated with an insecticide or insect repellant, such as Permethrin. In use, the insect repellant device may be effective at preventing biting insects, such as ticks, from crawling onto the user, for example from crawling up the legs of the user.